← Eichor
Study identifier: NCT06956144 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients

Condition: Tumor · Carbonic Anhydrase IX  ·  Sponsor: The First Affiliated Hospital of Xiamen University

PhaseN/A
Planned participants113
Who can joinAll sexes, 18 Years to 74 Years
Healthy volunteersYes

About this study

To evaluate the efficacy of targeted CAIX-specific probe PET imaging in the diagnosis and staging of kidney cancer, as well as to assess its role in prognosis prediction and treatment evaluation for kidney cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Haojun Chen  ·  86-592-2137077  ·  leochen0821@foxmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000Xiamen, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06956144